A Phase I, Randomized, Double-Blind, Placebo-Controlled, Study of Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Alirocumab (Primary)
- Indications Atherosclerosis; Coronary artery disease; Dyslipidaemias; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- 12 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 12 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 03 Sep 2022 Planned number of patients changed from 30 to 100.